Ginwa Enterprise Group Inc (600080) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ginwa Enterprise Group Inc (600080) has a cash flow conversion efficiency ratio of 0.019x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥29.81 Million ≈ $4.36 Million USD) by net assets (CN¥1.58 Billion ≈ $231.66 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Ginwa Enterprise Group Inc (600080) market capitalisation for the company's overall valuation and market capitalisation.
Ginwa Enterprise Group Inc - Cash Flow Conversion Efficiency Trend (1998–2025)
This chart illustrates how Ginwa Enterprise Group Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Ginwa Enterprise Group Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ginwa Enterprise Group Inc ranked by their cash flow conversion efficiency. Explore Ginwa Enterprise Group Inc earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Talon Capital Corp. Class A Ordinary Shares
NASDAQ:TLNC
|
-0.002x |
|
Drugs Made In America Acquisition Corp. Ordinary Shares
NASDAQ:DMAA
|
-0.002x |
|
Amtech Systems Inc
NASDAQ:ASYS
|
0.010x |
|
Hunter Group ASA
OL:HUNT
|
0.512x |
|
Ainsworth Game Technology Ltd
AU:AGI
|
-0.017x |
|
PRG Corporation Public Company Limited
BK:PRG
|
-0.025x |
|
Shanghai Baolijia Chemical Co. Ltd.
SHE:301037
|
N/A |
|
Pruksa Holding Public Company Limited
BK:PSH
|
0.039x |
Annual Cash Flow Conversion Efficiency for Ginwa Enterprise Group Inc (1998–2025)
The table below shows the annual cash flow conversion efficiency of Ginwa Enterprise Group Inc from 1998 to 2025. View Ginwa Enterprise Group Inc stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥1.56 Billion ≈ $228.04 Million |
CN¥24.77 Million ≈ $3.62 Million |
0.016x | +128.23% |
| 2024-12-31 | CN¥1.56 Billion ≈ $228.20 Million |
CN¥10.86 Million ≈ $1.59 Million |
0.007x | -81.16% |
| 2023-12-31 | CN¥1.64 Billion ≈ $239.75 Million |
CN¥60.55 Million ≈ $8.86 Million |
0.037x | +18.34% |
| 2022-12-31 | CN¥1.68 Billion ≈ $246.39 Million |
CN¥52.58 Million ≈ $7.69 Million |
0.031x | +69.04% |
| 2021-12-31 | CN¥1.66 Billion ≈ $242.36 Million |
CN¥30.59 Million ≈ $4.48 Million |
0.018x | -31.70% |
| 2020-12-31 | CN¥1.72 Billion ≈ $251.89 Million |
CN¥46.56 Million ≈ $6.81 Million |
0.027x | -58.36% |
| 2019-12-31 | CN¥1.72 Billion ≈ $251.06 Million |
CN¥111.45 Million ≈ $16.31 Million |
0.065x | +294.35% |
| 2018-12-31 | CN¥1.77 Billion ≈ $259.22 Million |
CN¥29.18 Million ≈ $4.27 Million |
0.016x | -57.02% |
| 2017-12-31 | CN¥1.12 Billion ≈ $163.66 Million |
CN¥42.87 Million ≈ $6.27 Million |
0.038x | -1.25% |
| 2016-12-31 | CN¥1.07 Billion ≈ $157.13 Million |
CN¥41.68 Million ≈ $6.10 Million |
0.039x | +33.85% |
| 2015-12-31 | CN¥1.05 Billion ≈ $153.06 Million |
CN¥30.33 Million ≈ $4.44 Million |
0.029x | -13.83% |
| 2014-12-31 | CN¥1.02 Billion ≈ $149.29 Million |
CN¥34.33 Million ≈ $5.02 Million |
0.034x | -23.57% |
| 2013-12-31 | CN¥998.35 Million ≈ $146.09 Million |
CN¥43.96 Million ≈ $6.43 Million |
0.044x | +132.20% |
| 2012-12-31 | CN¥962.22 Million ≈ $140.80 Million |
CN¥18.25 Million ≈ $2.67 Million |
0.019x | -80.86% |
| 2011-12-31 | CN¥918.45 Million ≈ $134.40 Million |
CN¥91.02 Million ≈ $13.32 Million |
0.099x | +76.26% |
| 2010-12-31 | CN¥724.97 Million ≈ $106.09 Million |
CN¥40.76 Million ≈ $5.96 Million |
0.056x | +3.91% |
| 2009-12-31 | CN¥691.57 Million ≈ $101.20 Million |
CN¥37.42 Million ≈ $5.48 Million |
0.054x | -69.61% |
| 2008-12-31 | CN¥696.22 Million ≈ $101.88 Million |
CN¥123.96 Million ≈ $18.14 Million |
0.178x | +1452.87% |
| 2007-12-31 | CN¥747.13 Million ≈ $109.33 Million |
CN¥-9.83 Million ≈ $-1.44 Million |
-0.013x | -228.44% |
| 2006-12-31 | CN¥702.59 Million ≈ $102.81 Million |
CN¥-2.82 Million ≈ $-411.98K |
-0.004x | +54.64% |
| 2005-12-31 | CN¥781.05 Million ≈ $114.29 Million |
CN¥-6.90 Million ≈ $-1.01 Million |
-0.009x | -109.93% |
| 2004-12-31 | CN¥881.06 Million ≈ $128.93 Million |
CN¥78.36 Million ≈ $11.47 Million |
0.089x | -0.45% |
| 2003-12-31 | CN¥869.84 Million ≈ $127.28 Million |
CN¥77.72 Million ≈ $11.37 Million |
0.089x | +32.72% |
| 2002-12-31 | CN¥850.75 Million ≈ $124.49 Million |
CN¥57.27 Million ≈ $8.38 Million |
0.067x | -30.49% |
| 2001-12-31 | CN¥829.75 Million ≈ $121.42 Million |
CN¥80.36 Million ≈ $11.76 Million |
0.097x | -20.01% |
| 2000-12-31 | CN¥789.96 Million ≈ $115.60 Million |
CN¥95.64 Million ≈ $14.00 Million |
0.121x | -2.80% |
| 1999-12-31 | CN¥480.99 Million ≈ $70.38 Million |
CN¥59.91 Million ≈ $8.77 Million |
0.125x | -2.69% |
| 1998-12-31 | CN¥401.15 Million ≈ $58.70 Million |
CN¥51.35 Million ≈ $7.51 Million |
0.128x | -- |
About Ginwa Enterprise Group Inc
Ginwa Enterprise (Group) Inc. researches, develops, produces, markets, and sells traditional Chinese medicines, biological drugs, and chemical drugs primarily in China. The company offers a range of orthopaedics, immunity, children, and general medicines in various dosage forms, including tablets, capsules, granules, powders, mixtures, oral solutions, syrups, and external solutions. It is also in… Read more